跳到正文
GMP干货· 心作流云·· 19 天前AI 评分75

PIC/S发布PI 058-1解读无菌药品生产附录1修订内容

PIC/S发布了EU GMP附录1解读文件

AI 导读

PIC/S发布PI 058-1《无菌药品生产附录1最重要变更的解读(2022)》,该文件于2026年10月16日由PIC/S委员会通过,并于10月28日生效。文件用于支持检查协调开展和统一技术解读,PIC/S明确其不引入新的GMP要求,而是解释现有要求。

正文

PIC/S has published a new interpretation of the revised Annex 1 in PI 058-1, "Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022)". The document was adopted by the PIC/S Committee on 16 October 2026 and entered into force on 28 October 2026. Its purpose is to support the harmonised conduct of inspections and provide a common technical interpretation of key questions that have arisen since the Annex was revised and implemented. PIC/S explicitly clarifies that PI 058-1 is not intended to introduce new GMP requirements, but to explain existing ones.

PIC/S已在PI 058-1《无菌药品生产附录1最重要变更的解读(2022)》中发布了对修订版附录1的新解读。该文件于2026年10月16日由PIC/S委员会通过,并于2026年10月28日生效。其目的是支持检查工作的协调开展,并就附录1修订和实施以来出现的关键问题提供统一的技术解读。PIC/S 明确澄清,PI 058-1 并非意在引入新的GMP要求,而是对现有要求进行解释。

The document's origins are particularly relevant. The initial draft was prepared by Swissmedic in 2023 (I-SMI.TI.25e). It served as the starting point for the work of the joint PIC/S-EMA-WHO Working Group on the implementation of the revised Annex 1. The draft was subsequently reviewed by PIC/S members, the EMA working group and WHO. The aim is to ensure a consistent technical interpretation across PIC/S, the EU and WHO.

该文件的起源尤为值得关注。初稿由瑞士Swissmedic于2023年编制(I-SMI.TI.25e)(相关文章见:进入A/B级洁净区前的物料和设备的转移验证如何进行?),它成为PIC/S-EMA-WHO联合工作组推进修订版附录1实施工作的起点。该草案随后经PIC/S成员、EMA工作组和WHO审阅。其目标是确保PIC/S、欧盟和WHO之间技术解读的一致性。

PIC/S explains that the draft prepared by Swissmedic in 2023served as the basis for the joint PIC/S-EMA-WHO Working Group. The resulting document was then reviewed internationally and is intended to support a harmonised technical interpretation. It is therefore not simply an unchanged adoption of the Swissmedic Q&As. At the same time, many topics were already covered in I-SMI.TI.25e, including material transfers, WFI, PUPSIT, single-use systems, environmental monitoring and APS. PI 058-1 revisits these questions and further explains them within a harmonised framework.

PIC/S解释称,Swissmedic于2023年编制的草案构成了PIC/S-EMA-WHO联合工作组的基础。由此形成的文件随后在国际范围内进行了审阅,旨在支持统一的技术解读。因此,它并非对Swissmedic问答的简单原样采纳。与此同时,I-SMI.TI.25e中已涵盖许多主题,包括物料传递、WFI、PUPSIT、一次性使用系统、环境监测和 APS(无菌工艺模拟)。PI 058-1重新审视了这些问题,并在统一框架内对其作了进一步阐释。

One clear example of the expanded scope is the section on scope. The Swissmedic Q&As begin by asking how Annex 1 applies to ATMPs. PI 058-1 instead explicitly addresses whether a CCS may also be relevant to the manufacture of non-sterile products and further explains the structure and regular review of the CCS. Other points addressed in greater detail include the distinction between VHP bio-decontamination and sterilisation, as well as requirements for initial personnel qualification and possible disqualification.

扩大范围的一个明显例子是"范围"部分。Swissmedic的问答首先询问附录1如何适用于 ATMP(先进治疗药品)。PI 058-1则明确探讨了CCS(污染控制策略)是否也可能与非无菌产品的生产相关,并进一步阐释了CCS的结构和定期评审。其他阐述更为详细的内容包括VHP生物去污与灭菌之间的区别,以及初始人员资质认定和可能的资格取消要求。

What are the main topics covered by PI 058-1?

PI 058-1 涵盖的主要主题有哪些?

  • Scope and general principles: CCS, material testing and risk-based interim measures for facilities that are not yet fully compliant; the objective remains to achieve full compliance with the requirements.

    范围与一般原则:CCS、物料检测,以及对尚未完全合规的设施采取基于风险的临时措施;目标仍是实现对所有要求的完全合规。

  • Premises and equipment: Material transfers, isolator risk assessments, airflow, disinfection, and the distinction between bio-decontamination and sterilisation. VHP is not treated as a sterilisation method in all cases.

    厂房与设备:物料传递、隔离器风险评估、气流、消毒,以及生物去污与灭菌之间的区别。VHP并非在所有情况下都被视为一种灭菌方法。

  • Utilities and personnel: WFI monitoring, process gases, qualification in aseptic behaviour, and the conditions for unsupervised access to Grade A and B areas.

    公用设施与人员:WFI监测、工艺气体、无菌行为方面的资质认定,以及无监督进入A级和B级区域的条件。

  • Production and specific technologies: Container and single-use system integrity, sterilisation validation, PUPSIT, aseptic connections, and the design of Aseptic Process Simulations (APS).

    生产与特定技术:容器和一次性使用系统的完整性、灭菌验证、PUPSIT、无菌连接,以及无菌工艺模拟(APS)的设计。

  • Environmental and process monitoring, and QC: Trend assessment and alert/action limits, Rapid Microbiological Methods (RMM) and the conditions for using them as alternatives or supplementary rapid methods, APS scope and frequency, and bioburden testing before final sterilisation.

    环境与工艺监测及QC:趋势评估与警戒限/纠偏限、快速微生物方法(RMM)及其作为替代或补充快速方法使用的条件、APS 的范围和频率,以及最终灭菌前的生物负载检测。

The CCS is a central theme throughout the document. The ECA guide "How to Develop and Document a Contamination Control Strategy," can also be used as practical support when preparing a CCS. It describes a structured approach that includes mapping processes, identifying potential sources of contamination, assessing risks, and defining preventive controls and responsibilities. The guide complements PI 058-1 as a support, but does not replace regulatory requirements or a site-specific assessment. A CCS must be tailored to the product, process, facility and existing control systems.

CCS是贯穿全文的核心主题。ECA指南《如何开发和记录污染控制策略》也可在编制CCS时作为实用支持使用。该指南描述了一种结构化方法,包括流程映射、识别潜在污染源、评估风险,以及界定预防性控制措施和责任。该指南作为支持性材料对PI 058-1形成补充,但并不取代监管要求或针对具体场地的评估。CCS 必须根据产品、工艺、设施和现有控制系统量身定制。

In summary, the new PIC/S Q&A document, PI 058-1, is primarily an interpretative and harmonisation step. Manufacturers and inspectors would be well advised to focus specifically on the CCS, procedures and qualification programmes covering the topics outlined – particularly where national Q&As or internal interpretations have thus far served as guidance.

总之,新的 PIC/S问答文件PI 058-1主要是一项解读与协调举措。建议生产企业和检查员特别关注CCS、程序以及涵盖上述主题的资质认定计划——尤其是在国家问答或内部解读迄今一直作为指导依据的情况下。

原文来自ECA网站,点击“阅读原文”可查看PIC/S文件原文。

来源:GMP干货 · mp.weixin.qq.com

事件后续 · 1

查看事件全部